Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles

Abstract

Curcumin has shown considerable pharmacological activity, including anti-inflammatory, but its poor bioavailability and rapid metabolization have limited its application. The purpose of the present study was to formulate curcumin-solid lipid n anoparticles (curcumin-SLNs) to improve its therapeutic efficacy in an ovalbumin (OVA)-induced allergic rat model of asthma. A solvent injection method was used to prepare the curcumin-SLNs. Physiochemical properties of curcumin-SLNs were characterized, and release experiments were performed in vitro. The pharmacokinetics in tissue distribution was studied in mice, and the therapeutic effect of the formulation was evaluated in the model. The prepared formulation showed an average size of 190 nm with a zeta potential value of −20.7 mV and 75% drug entrapment efficiency. X-ray diffraction analysis revealed the amorphous nature of the encapsulated curcumin. The release profile of curcumin-SLNs was an initial burst followed by sustained release. The curcumin concentrations in plasma suspension were significantly higher than those obtained with curcumin alone. Following administration of the curcumin-SLNs, all the tissue concentrations of curcumin increased, especially in lung and liver. In the animal model of asthma, curcumin-SLNs effectively suppressed airway hyperresponsiveness and inflammatory cell infiltration and also significantly inhibited the expression of T-helper-2-type cytokines, such as interleukin-4 and interleukin-13, in bronchoalveolar lavage fluid compared to the asthma group and curcumin-treated group. These observations implied that curcumin-SLNs could be a promising candidate for asthma therapy.

Curcumin-loaded PLGA Nanoparticles Conjugated with Anti-P-glycoprotein Antibody to Overcome Multidrug Resistance

“…The concentration of Cur in the serum of Cur-NPs-and CurNPs-APgp-treated mice was more prolonged than with free Cur. This may be due to the inherent properties of NPs, which may prevent the rapid metabolism of Cur, provide a sustained release, and change the drug pharmacokinetics to improve efficacy (Manjunath and Venkateswarlu, 2005;Wang et al, 2012). These results were consistent with our previous ex vivo data from a Cur-releasing assay, which showed a sustained and prolonged release of Cur in the buffer for up to 10 days (Punfa et al, 2012).…”

In vitro antioxidant activity and in vivo antifatigue effect of layered double hydroxide nanoparticles as delivery vehicles for folic acid

“…This is because PCS is used for hydrodynamic diameter determination, while TEM is used for characterization of particles in the dried state. 27 In vitro antioxidant activities of folic acid-lDh…”

Formulation, characterization, and geno/cytotoxicity studies of galbanic acid-loaded solid lipid nanoparticles

“…Delivery of lipophilic natural compounds by SLNs is a promising strategy that has attracted the attention of both phytochemist and pharmaceutical scientist to overcome their poor solubility, and to increase their pharmaceutical behaviors. In this context, fabrication of various active natural compounds such as acetylshikonin (Eskandani & Nazemiyeh, 2014), curcumin (Wang et al, 2012), frankincense and myrrh essential oils (Shi et al, 2012), tetrandrine (Li et al, 2006), and andrographolide (Parveen et al, 2013) in SLNs have been reported until now. Apparently, however, no investigation has been made to deliver galbanic acid (GBA) to the cancerous cells by the SLNs until now.…”